Sagimet Biosciences (NASDAQ: SGMT) — Company Overview, News & Financial Data
Sagimet Biosciences is a biopharmaceutical company focused on developing novel therapeutics for metabolic diseases like NASH.
Sagimet Biosciences
Sagimet Biosciences (NASDAQ:SGMT) is a biopharmaceutical company dedicated to developing a range of novel therapeutics aimed at addressing critical needs in metabolic diseases, with a significant focus on nonalcoholic steatohepatitis (NASH) and other liver-related disorders. Their innovative approach leverages unique insights into metabolism and disease mechanisms to design targeted, effective treatments. Currently, Sagimet Biosciences is advancing its lead candidate through clinical trials, demonstrating a commitment to improving patient outcomes in areas with significant unmet medical needs. The company's objectives are deeply rooted in advancing healthcare through groundbreaking research, aiming to deliver transformative therapies to patients worldwide.
Snapshot
Operations
Products and/or services of Sagimet Biosciences
- FASN Inhibitor Program focused on developing treatments for metabolic diseases, NASH (non-alcoholic steatohepatitis), and cancers.
- Clinical trials for non-alcoholic steatohepatitis (NASH) treatment with novel FASN inhibitors.
- Development of novel therapeutics targeting fatty acid synthase (FASN) to address various cancers.
- Research on metabolic diseases treatments leveraging their proprietary technology platform.
- Partnerships for advancing research and development in therapies for liver diseases and metabolic disorders.
- Pipeline expansion into new therapeutic areas by exploring the role of FASN in different diseases.
Sagimet Biosciences executive team
- David A. HappelCEO, President & Director
- Elizabeth RozekChief Legal & Administrative Officer
- Urs GreberCo-Founder
- Lucas PelkmansCo-Founder
- Thierry ChaucheCFO & Principal Accounting Officer
- Marie O'FarrellChief Scientific Officer
- Robert D'UrsoSenior Vice President of New Products
- Andreas GrauerChief Medical Officer
Latest news about Sagimet Biosciences
Sagimet reports 57% IGA success at Week 52
United StatesSagimet reports 52-week denifanstat acne trial results
United StatesSagimet advances Phase 3 acne trial for denifanstat
United StatesSagimet to present new Phase 2b denifanstat data at fueling MASH symposium
United StatesSagimet Biosciences advances MASH and acne programs following key regulatory milestones
United StatesSagimet partner reports positive phase 3 long-term acne data for denifanstat
United States
Key financials
Reported results for Sagimet Biosciences, in USD.
- Market cap
- 761.6M
- Revenue (TTM)
- 0
- P/E ratio
- —
- EPS (diluted, TTM)
- -1.3
- Dividend yield
- —
- Profit margin
- 0.0%
| Fiscal year end | Revenue | Operating income | Net income |
|---|---|---|---|
| 0 | -56.9M | -51M | |
| 0 | -54.5M | -45.6M | |
| 2M | -30.7M | -27.9M | |
| 0 | -31.1M | -30.5M |